The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors
The study of targeted NY-ESO-1 T cell receptor (TCR) genetic modified autologous T cells treatment of advanced solid tumors

1. The main purpose - security and ORR;
2. A secondary purpose - median progression-free surial;1 year, 2 years, total 5 years survival rate;The quality of life.
Advanced Malignant Solid Tumors
OTHER: TCR - T cell therapy
overall survival (OS), From date of randomization until the date of date of death from any cause, whichever came first, assessed up to 36 months
The study of targeted NY-ESO-1 T cell receptor (TCR) genetic modified autologous T cells treatment of advanced solid tumors

1. The main purpose - security and ORR;
2. A secondary purpose - median progression-free surial;1 year, 2 years, total 5 years survival rate;The quality of life.